CN114516799B - 一种吲哚布芬关键中间体2-(4-硝基苯基)丁酸的合成方法 - Google Patents
一种吲哚布芬关键中间体2-(4-硝基苯基)丁酸的合成方法 Download PDFInfo
- Publication number
- CN114516799B CN114516799B CN202011313308.3A CN202011313308A CN114516799B CN 114516799 B CN114516799 B CN 114516799B CN 202011313308 A CN202011313308 A CN 202011313308A CN 114516799 B CN114516799 B CN 114516799B
- Authority
- CN
- China
- Prior art keywords
- formula
- acid
- reaction
- nitrophenyl
- indobufen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- AYDXAULLCROVIT-UHFFFAOYSA-N indobufen Chemical compound C1=CC(C(C(O)=O)CC)=CC=C1N1C(=O)C2=CC=CC=C2C1 AYDXAULLCROVIT-UHFFFAOYSA-N 0.000 title claims abstract description 12
- 229960003422 indobufen Drugs 0.000 title claims abstract description 11
- XBGNOMBPRQVJSR-UHFFFAOYSA-N 2-(4-nitrophenyl)butanoic acid Chemical compound CCC(C(O)=O)C1=CC=C([N+]([O-])=O)C=C1 XBGNOMBPRQVJSR-UHFFFAOYSA-N 0.000 title claims abstract description 10
- 238000001308 synthesis method Methods 0.000 title claims description 5
- 238000006243 chemical reaction Methods 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 18
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 239000000126 substance Substances 0.000 claims abstract description 9
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000003960 organic solvent Substances 0.000 claims abstract description 6
- 230000008569 process Effects 0.000 claims abstract description 4
- 230000002378 acidificating effect Effects 0.000 claims abstract description 3
- 230000009471 action Effects 0.000 claims abstract description 3
- 230000003301 hydrolyzing effect Effects 0.000 claims abstract description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 27
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 230000035484 reaction time Effects 0.000 claims description 4
- 239000012312 sodium hydride Substances 0.000 claims description 4
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- 238000006396 nitration reaction Methods 0.000 abstract description 3
- 230000002194 synthesizing effect Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 7
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 229960004187 indoprofen Drugs 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- SUSQOBVLVYHIEX-UHFFFAOYSA-N phenylacetonitrile Chemical compound N#CCC1=CC=CC=C1 SUSQOBVLVYHIEX-UHFFFAOYSA-N 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- ZAQJJAIJSZCNLQ-UHFFFAOYSA-N 2-(2-nitrophenyl)butanoic acid Chemical compound CCC(C(O)=O)C1=CC=CC=C1[N+]([O-])=O ZAQJJAIJSZCNLQ-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical group [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical group [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- MNDIARAMWBIKFW-UHFFFAOYSA-N 1-bromohexane Chemical compound CCCCCCBr MNDIARAMWBIKFW-UHFFFAOYSA-N 0.000 description 1
- WAPLXGPARWRGJO-UHFFFAOYSA-N 2-(4-aminophenyl)butanoic acid Chemical compound CCC(C(O)=O)C1=CC=C(N)C=C1 WAPLXGPARWRGJO-UHFFFAOYSA-N 0.000 description 1
- PXNJGLAVKOXITN-UHFFFAOYSA-N 2-(4-nitrophenyl)acetonitrile Chemical compound [O-][N+](=O)C1=CC=C(CC#N)C=C1 PXNJGLAVKOXITN-UHFFFAOYSA-N 0.000 description 1
- FXHXUBNWGNUKGM-UHFFFAOYSA-N 2-(4-nitrophenyl)butanenitrile Chemical compound CCC(C#N)C1=CC=C([N+]([O-])=O)C=C1 FXHXUBNWGNUKGM-UHFFFAOYSA-N 0.000 description 1
- 208000013544 Platelet disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical group [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001546 nitrifying effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical group [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 229910052611 pyroxene Inorganic materials 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
- C07C201/06—Preparation of nitro compounds
- C07C201/12—Preparation of nitro compounds by reactions not involving the formation of nitro groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
- C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
Abstract
本发明公开了一种吲哚布芬关键中间体2‑(4‑硝基苯基)丁酸的合成方法,所述的合成方法包括:在有机溶剂中,在碱性物质的作用下,式Ⅰ所示的化合物与溴乙烷反应得到式Ⅱ所示的化合物,再将式Ⅱ所示的化合物在酸性条件下水解得到式Ⅲ所示的目标产物。本发明所述的方法步骤简单,操作方便,反应无硝化过程,安全性高,污染小,产物的收率高。
Description
技术领域
本发明属于化合物合成领域,具体涉及一种吲哚布芬关键中间体2-(4-硝基苯基)丁酸的合成方法。
背景技术
吲哚布芬(indobufen)化学名为2-[4-(1-氧代2-异吲哚啉基)苯基]丁酸,是由美国辉瑞公司研发的一种外消旋体混合物,它能选择的作用于循环的血小板,阻断血栓形成,抑制血小板因子释放而发挥抗血小板聚集作用,这种抑制是可逆的,不改变血浆参数,无损血小板功能,并使变异常的血小板功能恢复正常。与同类药物相比,吲哚布芬抑制血小板因子,抗血小板聚集效果是水杨酸的2~5倍,较之有轻微持续时间更短的出血时间。
高学民等在《抗凝药吲哚布芬的合成》(中国医药工业杂志,1989,20(11))、郑庚修等在《吲哚布芬的制备工艺》(中国医药工业杂志,1991,22(7))、发明专利CN 106631974 B中公开的吲哚布芬或吲哚布芬中间体的合成路线均以2-(4-硝基苯基)丁酸为起始物料,目前关于2-(4-硝基苯基)丁酸的合成报道非常少,例如郑庚修等在《吲哚布芬的制备工艺》(中国医药工业杂志,1991,22(7))中公开的吲哚布芬制备路线中显示,2-(4-氨基苯基)丁酸可以通过苯乙腈和溴己烷反应,然后经过硝化得到。但受环评影响,涉及硝化反应的生产受严格控制,为了降低风险,十分必要开发一种吲哚布芬关键中间体2-(4-硝基苯基)丁酸新的制备方法。
发明内容
为解决现有技术存在的缺陷,本发明提供了一种吲哚布芬关键中间体2-(4-硝基苯基)丁酸新的合成方法。
本发明采用如下技术方案:
一种吲哚布芬关键中间体2-(4-硝基苯基)丁酸的合成方法包括如下步骤:
(1)在有机溶剂中,在碱性物质的作用下,式Ⅰ所示的化合物与溴乙烷反应得到式Ⅱ所示的化合物;
(2)式Ⅱ所示的化合物在酸性条件下水解得到式Ⅲ所示的目标产物;
进一步,步骤(1)中,所述的碱性物质为碳酸钠、氢氧化钠、氢氧化钾、氢化钠或氨基钠。
进一步,步骤(1)中,所述的式Ⅰ所示的化合物与溴乙烷、碱性物质的比例关系为1:0.5~2:0.5~2;再进一步,式Ⅰ所示的化合物与氢化钠摩尔比优选为1:1.2,式Ⅰ所示的化合物与除氢化钠之外的碱性物质的摩尔比优选为1:3。
进一步,步骤(1)中,所述的反应温度在室温下进行,反应时间为8~20h,优选为12h。
进一步,步骤(1)中,所述反应在有机溶剂中进行,所述的有机溶剂为四氢呋喃、二氧六环、N,N-二甲基甲酰胺。
进一步,步骤(2)中,所述的酸为硫酸、盐酸、三氟甲磺酸、醋酸,优选为50%浓硫酸。
进一步,步骤(2)中,所述的α-(对硝基苯基)丁腈与酸的摩尔比为1:1~6,优选为1:5。
进一步,步骤(2)中,所述的反应时间为5~30h,优选为24h,反应温度为80~120℃,优选为100℃。
与现有技术相比,本发明的有益效果在于:
本发明所述的方法步骤简单,操作方便,反应无硝化过程,安全性高,污染小,产物的收率高。
具体实施方式
以下实施例作为对本发明的进一步说明,不应将其视为对本发明的限制。
实施例中所述的SM1原料可购买,亦可根据文献制备得到:SM1的制备
在50ml三颈瓶中将7ml硝酸和10ml硫酸混和,冷却至10℃,滴加苯乙腈4ml(4.06g,34.66mmol)。加毕,室温搅拌1小时,倒入50ml冰水中。过滤,用乙醇重结晶,干燥,得对硝基苯乙腈4.85g,产率:86.30%,mp:110~112℃(文献mp:112~114℃,中国医药工业杂志,1993,24(6):276)。
实施例1
在反应瓶中加入SM1(1.62g,10.00mmol)和氢氧化钠(1.20g,30.00mmol),溶于DMF中,搅拌下滴入溴乙烷(1.63g,15.00mmol),室温反应12h。反应完毕后将反应液倒入水中,用乙酸乙酯萃取,合并有机相,饱和食盐水洗涤,无水硫酸钠干燥,柱层析纯化,洗脱剂正己烷:乙酸乙酯=10:1,得到淡黄色油状液体A00 1.50g,收率79%。1H NMR(60MHz,CDCl3)δ8.47–8.03(m,2H),7.78–7.35(m,2H),3.89(t,J=7.0Hz,1H),2.34–1.73(m,2H),1.31–0.93(m,3H).HRMS(ESI):found 189.0765[M+H]-
实施例2
在反应瓶中加入SM1(1.62g,10.00mmol)溶于DMF中,冷却至0℃,冰浴下加入NaH(0.28g,12.00mmol),搅拌半小时后滴入溴乙烷(1.63g,15.00mmol),撤去冰浴,室温反应12h。反应完毕后将反应液倒入水中,用乙酸乙酯萃取,合并有机相,饱和食盐水洗涤,无水硫酸钠干燥,柱层析纯化,洗脱剂正己烷:乙酸乙酯=10:1得到淡黄色油状液体A00 1.56g,收率85%。
1H NMR(60MHz,CDCl3)δ8.47–8.03(m,2H),7.78–7.35(m,2H),3.89(t,J=7.0Hz,1H),2.34–1.73(m,2H),1.31–0.93(m,3H).HRMS(ESI):found 189.0765[M-H]-
实施例3
将实施例1中的氢氧化钠替换为三乙胺(4.09mL,30.00mmol),其余条件参数不变,不发生反应,无法得到目标产物A00。
实施例4
将实施例1中的氢氧化钠替换为叔丁醇钾(3.36g,30.00mmol),其余条件参数不变,不发生反应,无法得到目前产物A00。
实施例5
将实施例1中的氢氧化钠替换为甲醇钠(1.62g,30.00mmol),其余条件参数不变,不发生反应,无法得到目前产物A00。
实施例6
将实施例1中的氢氧化钠替换为碳酸钾(4.14g,30.00mmol),其余条件参数不变,不发生反应,无法得到目前产物A00。
实施例7
将实施例1中的氢氧化钠替换为碳酸铯(9.78g,30.00mmol),其余条件参数不变,不发生反应,无法得到目前产物A00。
实施例8
在反应瓶中加入A00(0.20g,1.05mmol),溶于5mL二氧六环中,搅拌下滴入50%浓硫酸(1.03mL,5.25mmol),100℃反应24h。反应完毕后,反应液旋干,加水,NaOH调pH至10~12,二氯甲烷萃取,弃去有机相,水相用HCl调pH至3~6,二氯甲烷萃取,有机相饱和食盐水洗,无水硫酸钠干燥,旋干得到淡黄色固体B00 1.50g,收率71%。
1H NMR(60MHz,CDCl3)δ8.19(d,J=8.6Hz,2H),7.49(d,J=8.6Hz,2H),3.61(t,J=7.4Hz,1H),1.96(dp,J=13.8,6.8Hz,2H),0.93(t,J=7.2Hz,3H).
HRMS(ESI):found 208.0615[M-H]-
对比例:
文献《吲哚布芬的制备工艺》中提供的文献Makosza M et al:OrganicSyntheses,ed by Masamune S l976,vol 5PP 91~93.John Wiley.New York由苯乙腈制备文献中的化合物3,收率为72%;
由化合物3制备2-(硝基苯基)丁酸的步骤为:将浓硝酸和浓硫酸各45ml置反应瓶中混合,冰浴冷却,搅拌下于0~5℃滴加3l8g(0.124mol),加完后继续搅拌1.5h,倒入冰水中,分出油层。将油状物加入H2SO4与H2O(1:1)100ml中,在搅拌下回流4h,冷却、倒入冷水100ml中滤出固体。以苯一石油醚重结晶,得5 11.5g二步连乘收率44.2%,mp 121~122℃。即由苯乙腈制备2-(硝基苯基)丁酸的收率为31.82%。
Claims (11)
1.一种吲哚布芬关键中间体2-(4-硝基苯基)丁酸的合成方法,其特征在于,包括如下步骤:
(1)在有机溶剂中,在碱性物质的作用下,式Ⅰ所示的化合物与溴乙烷反应得到式Ⅱ所示的化合物;
(2)式Ⅱ所示的化合物在酸性条件下水解得到式Ⅲ所示的目标产物;
所述的碱性物质为氢氧化钠或氢化钠。
2.如权利要求1所述的方法,其特征在于,步骤(1)中,所述的式Ⅰ所示的化合物与溴乙烷、碱性物质的物质的量之比为1:0.5~2:0.5~2。
3.如权利要求1所述的方法,其特征在于,步骤(1)中,所述的反应在室温下进行,反应时间为8~20h。
4.如权利要求1所述的方法,其特征在于,步骤(1)中,所述的反应在室温下进行,反应时间为12h。
5.如权利要求1所述的方法,其特征在于,步骤(1)中,所述反应在有机溶剂中进行,所述的有机溶剂为四氢呋喃、二氧六环、N,N-二甲基甲酰胺。
6.如权利要求1所述的方法,其特征在于,步骤(2)中,所述的酸为硫酸、盐酸、三氟甲磺酸、醋酸。
7.如权利要求1所述的方法,其特征在于,步骤(2)中,所述的酸为50%浓硫酸。
8.如权利要求1所述的方法,其特征在于,步骤(2)中,所述的式Ⅱ所示的化合物与酸的摩尔比为1:1~6。
9.如权利要求1所述的方法,其特征在于,步骤(2)中,所述的式Ⅱ所示的化合物与酸的摩尔比为1:5。
10.如权利要求1所述的方法,其特征在于,步骤(2)中,所述的反应时间为5~30h;反应温度为80~120℃。
11.如权利要求1所述的方法,其特征在于,步骤(2)中,所述的反应时间为24h;反应温度为100℃。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011313308.3A CN114516799B (zh) | 2020-11-20 | 2020-11-20 | 一种吲哚布芬关键中间体2-(4-硝基苯基)丁酸的合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011313308.3A CN114516799B (zh) | 2020-11-20 | 2020-11-20 | 一种吲哚布芬关键中间体2-(4-硝基苯基)丁酸的合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114516799A CN114516799A (zh) | 2022-05-20 |
CN114516799B true CN114516799B (zh) | 2024-02-20 |
Family
ID=81594780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011313308.3A Active CN114516799B (zh) | 2020-11-20 | 2020-11-20 | 一种吲哚布芬关键中间体2-(4-硝基苯基)丁酸的合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114516799B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4311696A (en) * | 1981-02-12 | 1982-01-19 | E. I. Du Pont De Nemours And Company | Substituted butanoic acid esters |
CN103342662A (zh) * | 2013-07-25 | 2013-10-09 | 南通瑞点化工科技有限公司 | 一种合成2-烷基苯乙腈的方法 |
WO2017121645A1 (en) * | 2016-01-15 | 2017-07-20 | Laboratorios Del Dr. Esteve, S.A. | 3-ethyl-3-phenylazepane derivatives having multimodal activity against pain |
-
2020
- 2020-11-20 CN CN202011313308.3A patent/CN114516799B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4311696A (en) * | 1981-02-12 | 1982-01-19 | E. I. Du Pont De Nemours And Company | Substituted butanoic acid esters |
CN103342662A (zh) * | 2013-07-25 | 2013-10-09 | 南通瑞点化工科技有限公司 | 一种合成2-烷基苯乙腈的方法 |
WO2017121645A1 (en) * | 2016-01-15 | 2017-07-20 | Laboratorios Del Dr. Esteve, S.A. | 3-ethyl-3-phenylazepane derivatives having multimodal activity against pain |
Non-Patent Citations (1)
Title |
---|
Direct amino acid-catalyzed cascade reductive alkylation of arylacetonitriles: high-yielding synthesis of ibuprofen analogs;Dhevalapally B. Ramachary 等;《Tetrahedron Letters》;第51卷(第40期);第5250页图解3、左栏第3段和右栏第2段 * |
Also Published As
Publication number | Publication date |
---|---|
CN114516799A (zh) | 2022-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101993407B (zh) | 用于制备西洛多辛的吲哚啉化合物及其制备方法 | |
EP2067768A1 (en) | A process for the preparation of (S)(+)-3-(aminomethyl)-5-methylhexanoic acid | |
FI91064C (fi) | Menetelmä terapeuttisesti vaikuttavien 3-(N-asyylietyyli-aminoalkyyli)-kromaanien ja -1,4-dioksaanien valmistamiseksi | |
JP3930736B2 (ja) | ピリジンメタノール化合物の製造方法 | |
JP2002544207A (ja) | 2,2−ジメチル−1,3−ジオキサン中間体の塩及びその製法 | |
CN114516799B (zh) | 一种吲哚布芬关键中间体2-(4-硝基苯基)丁酸的合成方法 | |
EP1937662B1 (en) | Process for the preparation of duloxetine | |
CA2477892C (en) | Process for synthesizing chiral n-aryl piperazines | |
NZ530153A (en) | Process for the production of the piperidine derivative fexofenadine | |
US5659051A (en) | Process of producing 2-cyano-4-oxo-4H-benzopyran compounds | |
TWI500596B (zh) | 合成3,4-二甲氧基雙環[4.2.0]辛-1,3,5-三烯-7-甲腈之方法,及於合成依伐布雷定(ivabradine)及其與醫藥上可接受酸之加成鹽之應用 | |
EP1611084A1 (en) | Process for the manufacture of n-alkoxalyl-alaninates | |
JP2003155259A (ja) | 芳香族アルデヒドの製造方法および新規な芳香族ジアルデヒド | |
CN114516800A (zh) | 一种2-(4-硝基苯基)丁酸的合成方法 | |
JP5407145B2 (ja) | 4’−ジアルコキシメチルビシクロへキシル−4−イルメタノール及びその製造方法 | |
EP0876352A1 (en) | Process | |
CN107556237B (zh) | 一种3-(2-苯乙基)-2-吡啶甲酰胺类化合物的制备方法 | |
JP2011084478A (ja) | フェノールの製造方法 | |
CN117917397A (zh) | 一种合成n,n-二羟甲基叔丁胺的方法 | |
JP4596804B2 (ja) | シラザプリルの製造方法 | |
CN116120164A (zh) | 一种2-丁基辛二酸的制备方法 | |
JPH02295946A (ja) | 置換されたビフエニルカルボン酸およびその製法 | |
TW202246235A (zh) | 製備鞘胺醇-1-磷酸酯受體促效劑的新穎方法 | |
JP2004026652A (ja) | β−アルコキシアクリロニトリル誘導体 | |
CN114524765A (zh) | 一种碱催化合成琥珀酸多西拉敏的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |